Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy

Clinical Cancer Research

Volumn 20, Issue 13, 2014, Pages 3550-3559

  Schwarzenberg, Johannes ^a,b,e   Czernin, Johannes ^a,b   Cloughesy, Timothy F ^c   Ellingson, Benjamin M ^c   Pope, Whitney B ^c   Grogan, Tristan ^d   Elashoff, David ^d   Geist, Cheri ^a,b   Silverman, Daniel H S ^a,b   Phelps, Michael E ^a   Chen, Wei ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Translational Imaging Division   (United States)

^c Department of Neurology ^*  (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXY 6 FLUORO PHENYLALANINE F 18; BEVACIZUMAB; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 6 FLUORODOPA F 18; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DOPA; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GLIOBLASTOMA; HUMAN; MALE; MEDICAL PARAMETERS; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; STANDARDIZED UPTAKE VALUE; SURVIVAL TIME; TUMOR VOLUME; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CANCER GRADING; DIAGNOSTIC USE; GLIOMA; METABOLISM; MORTALITY; PROGNOSIS; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; DIHYDROXYPHENYLALANINE; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84903196695     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1440     Document Type: Article

References (39)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114: 97-109.
2. Daumas-Duport C, Scheithauer BW, Kelly PJ. A histologic and cytologic method for the spatial definition of gliomas. Mayo Clin Proc 1987;62: 435-49.
3. Scott JN, Brasher PM, Sevick RJ, Rewcastle NB, Forsyth PA. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology 2002;59: 947-9.
4. Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007; 25: 4714-21.
5. Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Geist C, et al. 3′-Deoxy-3′-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med 2012;53: 29-36.
6. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001;42: 432-45.
7. Laverman P, Boerman OC, Corstens FH, Oyen WJ. Fluorinated amino acids for tumour imaging with positron emission tomography. Eur J Nucl Med Mol Imaging 2002;29: 681-90.
8. Herholz K, Holzer T, Bauer B, Schroder R, Voges J, Ernestus RI, et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 1998;50: 1316-22.
9. Bergstrom M, Collins VP, Ehrin E, Ericson K, Eriksson L, Greitz T, et al. Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [68Ga]EDTA, [11C]glucose, and [11C]methionine. J Comput Assist Tomogr 1983; 7: 1062-6.
10. Mosskin M, von Holst H, Bergstrom M, Collins VP, Eriksson L, Johnstrom P, et al. Positron emission tomography with 11C-methionine and computed tomography of intracranial tumours compared with histopathologic examination of multiple biopsies. Acta Radiol 1987;28: 673-81.
11. Chung JK, Kim YK, Kim SK, Lee YJ, Paek S, Yeo JS, et al. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo-or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging 2002; 29: 176-82.
12. Huang MC, Shih YH, Chen MH, Chung WY, Ho DM, Liu RS, et al. Malignancy of intracerebral lesions evaluated with 11C-methionine-PET. J Clin Neurosci 2005;12: 775-80.
13. Kim S, Chung JK, Im SH, Jeong JM, Lee DS, Kim DG, et al. 11Cmethionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 2005; 32: 52-9.
14. Popperl G, Kreth FW, Mehrkens JH, Herms J, Seelos K, Koch W, et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging 2007;34: 1933-42.
15. Hutterer M, Nowosielski M, Putzer D, Waitz D, Tinkhauser G, Kostron H, et al. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med 2011;52: 856-64.
16. 18F]Fluoroethyl-L-tyrosine PET in comparison to MRI. Eur J Nucl Med Mol Imaging 2013;40: 22-3.
17. Heiss WD, Wienhard K, Wagner R, Lanfermann H, Thiel A, Herholz K, et al. F-DOPA as an amino acid tracer to detect brain tumors. J Nucl Med 1996;37: 1180-2.
18. Becherer A, Karanikas G, Szabo M, Zettinig G, Asenbaum S, Marosi C, et al. Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine. Eur J Nucl Med Mol Imaging 2003;30: 1561-7.
19. Chen W, Silverman DH, Delaloye S, Czernin J, Kamdar N, Pope W, et al. 18F-FDOPA PET imaging of brain tumors: comparison study with 18FFDG PET and evaluation of diagnostic accuracy. J Nucl Med 2006; 47: 904-11.
20. Tripathi M, Sharma R, D'Souza M, Jaimini A, Panwar P, Varshney R, et al. Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas. Clin Nucl Med 2009;34: 878-83.
21. Ledezma CJ, Chen W, Sai V, Freitas B, Cloughesy T, Czernin J, et al. 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. Eur J Radiol 2009;71: 242-8.
22. Schiepers C, Chen W, Cloughesy T, Dahlbom M, Huang SC. 18FFDOPA kinetics in brain tumors. J Nucl Med 2007;48: 1651-61.
23. Fueger BJ, Czernin J, Cloughesy T, Silverman DH, Geist CL, Walter MA, et al. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J Nucl Med 2010;51: 1532-8.
24. Walter F, Cloughesy T, Walter MA, Lai A, Nghiemphu P, Wagle N, et al. Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspective. J Nucl Med 2012;53: 393-8.
25. Brix G, Zaers J, Adam LE, Bellemann ME, Ostertag H, Trojan H, et al. Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucl Med 1997;38: 1614-23.
26. Lartizien C, Comtat C, Kinahan PE, Ferreira N, Bendriem B, Trebossen R. Optimization of injected dose based on noise equivalent count rates for 2-and 3-dimensional whole-body PET. J Nucl Med 2002;43: 1268-78.
27. Namavari M, Bishop A, Satyamurthy N, Bida G, Barrio JR. Regioselective radiofluorodestannylation with [18F]F2 and [18F]CH3COOF: a high yield synthesis of 6-[18F]Fluoro-L-dopa. Int J Rad Appl Instrum A 1992;43: 989-96.
28. Bishop A, Satyamurthy N, Bida G, Hendry G, Phelps M, Barrio JR. Proton irradiation of [18O]O2: production of [18F]F2 and [18F]F2 + [18F] OF2. Nucl Med Biol 1996;23: 189-99.
29. Kinahan PE, Townsend DW, Beyer T, Sashin D. Attenuation correction for a combined 3D PET/CT scanner. Med Phys 1998;25: 2046-53.
30. Nuyts J, Michel C, Dupont P. Maximum-likelihood expectation-maximization reconstruction of sinograms with arbitrary noise distribution using NEC-transformations. IEEE Trans Med Imaging 2001;20: 365-75.
31. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28: 1963-72.
32. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Mischel PS, Pope WB. Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. Neuro Oncol 2011; 13: 401-9.
33. Kaplan E, Meier P. Nonparametric-estimation from incomplete observations. J Am Stat Assoc 1958;53: 457-81.
34. Langen KJ, Muhlensiepen H, Holschbach M, Hautzel H, Jansen P, Coenen HH. Transport mechanisms of 3-[123I]iodo-α-methyl-L-tyrosine in a human glioma cell line: comparison with [3H]methyl]-Lmethionine. J Nucl Med 2000;41: 1250-5.
35. Roelcke U, Radu EW, von Ammon K, Hausmann O, Maguire RP, Leenders KL. Alteration of blood-brain barrier in human brain tumors: comparison of [18F]fluorodeoxyglucose, [11C]methionine and rubidium-82 using PET. J Neurol Sci 1995;132: 20-7.
36. Spaeth N, Wyss MT, Weber B, Scheidegger S, Lutz A, Verwey J, et al. Uptake of 18F-fluorocholine, 18F-fluoroethyl-L-tyrosine, and 18F-FDG in acute cerebral radiation injury in the rat: implications for separation of radiation necrosis from tumor recurrence. J Nucl Med 2004;45: 1931-8.
37. Sasajima T, Miyagawa T, Oku T, Gelovani JG, Finn R, Blasberg R. Proliferation-dependent changes in amino acid transport and glucose metabolism in glioma cell lines. Eur J Nucl Med Mol Imaging 2004; 31: 1244-56.
38. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003; 9: 685-93.
39. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285: 1182-6.